A
lexandria Real Estate Equities (ARE) earns a “Buy” rating because its shares are undervalued, it offers a 6.3 % yield, and its long‑term prospects are solid. The company’s mega‑campus strategy, diversified tenant base, and key role in life‑science real estate provide resilient cash flows and support future growth. Recent occupancy dips are offset by improving leasing activity, a healthy development pipeline, and strong financials. With a forward P/FFO of 9.1—well below historical averages—ARE delivers attractive income, growth, and potential upside for patient investors. Investors seeking similar opportunities can access exclusive iREIT®+HOYA Capital subscriber portfolios.

    This market climate makes undervalued names in pharma and real‑estate especially appealing.

    **Disclosure**: I hold a long position in ARE shares or related derivatives. This article reflects my personal views and is not compensated beyond Seeking Alpha. I have no business ties to any company mentioned and am not an investment advisor. The content is informational only; readers should conduct their own due diligence before investing. Seeking Alpha’s disclaimer: past performance is not indicative of future results, and the views expressed may not represent Seeking Alpha’s overall stance. The analysts are independent contributors, not licensed advisors.